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Abstract. As the global population ages, there is increased interest in living longer and improving one’s quality of life in
later years. However, studying aging – the decline in body function – is expensive and time-consuming. And despite research
success to make model organisms live longer, there still aren’t really any feasible solutions for delaying aging in humans.
With space travel, scientists and engineers couldn’t know what it would take to get to the moon. They had to extrapolate
from theory and shorter-range tests. Perhaps with aging, we need a similar moonshot philosophy. And though “shot” might
imply medicine, perhaps we need to think beyond medical interventions. Like the moon once was, we seem a long way away
from provable therapies to increase human healthspan (the healthy period of one’s life) or lifespan (how long one lives).
This review therefore focuses on radical proposals. We hope it might stimulate discussion on what we might consider doing
significantly differently than ongoing aging research.

1. Introduction – Incrementalism & thinking
linear vs. in log-scale
Silicon Valley wants 10X engineers, that is people
who do 10X the work of the average engineer. Likewise, biomedical researchers starting their careers are
told by their senior colleagues to chase big findings
and ignore small effects. To aim for big increases in
human healthspan or lifespan (assuming the Earth can
handle the consequences and enough people want to),
let’s first consider the current state of aging delaying
therapies.
There are many ways to think about treating aging.
Most existing treatments treat specific aging conditions. They are in the form of drugs that improve
one area of the body that is diseased in aging populations. Drugs for diabetes (high blood glucose) and
osteoporosis (bone loss) are common examples. Currently, there are no FDA-approved remedies for aging
∗ Corresponding

author: Timothy R. Peterson, Department of
Internal Medicine, Division of Bone and Mineral Diseases,
Department of Genetics, Institute for Public Health, Washington
University School of Medicine, BJC Institute of Health, 425 S.
Euclid Ave., St. Louis, MO 63110, USA. E-mail: timrpeterson@
wustl.edu.

per se, i.e., to increase healthspan or lifespan. Experiments aimed at identifying new interventions for
aging have historically been done in species ranging from primates to mice to worms to yeast [1].
Yet, the pharmaceutical industry has become weary
of treatments that work in model systems only to
be proven to be ineffective in humans [2]. This is
unfortunately especially true for treatments for agingassociated chronic diseases [3]. Thus, considering
human clinical trials for aging therapies will take
years to play out, before jumping into them it is important to scrutinize the effect sizes seen in preclinical
models.
A less than encouraging sign for many of the lifespan experiments done in preclinical models, namely
in mammals such as mice, is that they have modest
effect sizes, often only having statistically significant
effects in one of the genders, and often only in specific
dietary and/or housing conditions [4]. Even inhibiting one of the most potent and well-validated aging
pathways [5–7], the mechanistic target of rapamycin
(mTOR) pathway [8] has arguably modest effects on
lifespan – a 12–24% increase in mice (14–23% in
females/9–26% in males) [9, 10]. Notably, rapamycin
has been associated with harmful effects, including
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increased risk of aggressive hematological malignancies and dramatic microbiome alterations [11].
Also, like most studies done in mice these experiments were done in a controlled environment which
limits pathogens exposure. This is relevant because
rapamycin is an immunosuppressant used clinically
in organ transplantation [12]. This suggests in a
real-world scenario where people’s immune systems
would be challenged regularly, it’s not clear
rapamycin would have a significant beneficial effect
on healthspan or lifespan.
This is all to ask, if rapamycin is one of the potential
best-case scenarios and might be predicted to have
a modest effect if any (and possibly a detrimental
one) in people, should it continue to receive so much
focus by the aging community? Note the problems
in the aging field with small and inconsistent effects
for the leading strategies aren’t specific to rapamycin.
The popular reactive oxygen species (ROS) theory of
aging [13] was challenged when it was found that
deleting the genes capable of detoxifying superoxide
are dispensable for worm lifespan [14]. In a related
example in worms, different labs produced dramatically different lifespan-modulating effect sizes with
the same with ROS-altering drug [15]. That worms
are simpler than mice and it took over at decade by
highly qualified labs to resolve inconsistent results
with a single ROS drug, again doesn’t bode well for
ROS-based therapies in the real world with people.
Treating individual aging-related diseases has
encountered roadblocks that should also call into
question whether we are on the optimal path for
human aging. Alzheimer’s and diabetes are particularly well-funded and well-researched aging-related
topics where there are still huge gaps in our understanding and lack of good treatment options. With
Alzheimer’s there has been considerable focus on
amyloid beta and tau, but targeting those molecules
hasn’t done much for Alzheimer’s so far leaving many
searching for answers [16, 17]. Regarding diabetes,
some people think insulin resistance is caused by
intracellular over-accumulation of lipids, but despite
many smart people working on it for decades, it isn’t
clear whether diacylglycerol [18], ceramide [19], or
other lipids might be the main culprit. The point is
when we spend collectively a long time on something that isn’t working well, such as manipulating a
single gene or biological process, it should seem natural to consider conceptually different approaches.
Herein we will discuss different therapeutic concepts
for aging that might push us beyond our current
thinking.

2. Beyond the reductionist one-hypothesis,
one-pathway, one-disease view
Perhaps the problem is that aging might not be a
single molecular pathway or collection of pathways
as we biologists typically understand pathways. Following the omnigenic model of complex disease [20],
aging might involve all genes. Therefore, if this is
true, would doing one thing to extend life, such as
inhibiting one pathway with a drug, really be expected
to do a lot?
Still, part of the omnigenic model is that there are
“hub”/”core” genes that are relatively more important than other genes. It is intuitive to target the genes
we consider to be most impactful, so if one drug
or manipulating one gene may not be good enough,
looking into synergistic combinations as we do with
treating AIDS [21] or cancer [22, 23] seems like a
next logical step.
One proof-of-concept, aging-limiting cocktail is
the Yamanaka pluripotency factors [24] that was
tested with good results in a mouse model of the premature aging condition, progeria [25]. Manipulating
both insulin-like growth factor (IGF) and sterolresponsive element binding protein (SREBP) also
produced strong synergistic healthspan-extending
effects [26]. Several other combinations have likewise been validated in model organisms [27, 28].
Using synergistic combinations has the potential
to lower the amount of each agent one has to use,
which should be beneficial in lowering their potential side effects [29, 30]. Still, the effect sizes from
combinations of a few factors might not be much
more than those of a single factor. To even begin
to contemplate 10X effects like Silicon Valley aims
for, we need to concentrate on the strategies that will
generate the most synergistic combinations (Fig. 1).
This is a challenge because of the number of possible combinations to be tested is a multiple of the
number of factors under consideration. Consider the
hypothetical that we had drugs targeting each of the
20,000 protein-coding human genes. Testing all those
in combination would be four hundred million combinations, which isn’t feasible today (noting that in
some contexts the effects of combinations of many
factors can be approximated by the effects of pairs,
which significantly reduces the number of combinations to test [31]). Potentially we might not need
to screen through to find the best combination and
we could just throw the kitchen sink at the problem
and perturb many genes at a time. There is precedence for the many-gene approach using CRISPR,
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Fig. 1. 10X healthspan/lifespan strategy #1. Identify maximally synergistic aging preventing factors, such as drugs or
gene manipulations. Four factors are depicted as needed to
promote the synergistic effects of an aging phenotype, ρ (rho),
in analogy to the Yamanaka pluripotency cocktail, which contains four factors. These synergistic factors, which could be
drugs and/or gene manipulations, will ideally be chosen from a
large list of candidates following systematic, unbiased, large-scale
experimentation.

where 62 retroviral genes were knocked out in the
pig liver to make these organs theoretically safer for
transplantation [32]. Yet there are regulatory hurdles
that need to be cleared for such an approach to be
accepted for human use. Currently the FDA requires
testing of the individual components of a combination treatment. However, one can envision a future
where the need will get so great that the FDA will
allow applications for cocktails without their individual components gaining approval first [33].
Even thinking of specific aging-associated conditions rather than aging per se, synergistic factors
could provide a valuable, new path forward. Because
the same core genes tend to be important across aging
conditions [34] this suggests there would be a benefit for researchers interested in specific conditions
to look at aging per se or other aging conditions
besides the one they’re studying to better understand
them. For physicians, it might also mean that when
the one-drug approach is failing like it is with neurodegenerative conditions, such as Alzheimer’s, they
might consider drug synergies with drugs that alleviate other aging-associated conditions. This would
be a form of drug repositioning [35] that already has
evidence it could work for Alzheimer’s. For example, drugs for several aging-related conditions such as
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heart disease [36, 37], diabetes [38], osteoporosis [39]
have all been shown to alleviate neurodegeneration in
various models.
Yamanaka started his pursuit of a pluripotency
cocktail with a short list of genes. If we were to make
a short list of molecular factors for aging what would
it look like? On this point, we’d like to make a plug for
factors that add back function to aging tissues. Many
existing strategies to increase healthspan or lifespan
involve taking something away from our cells, often
by inhibiting molecular pathways. Dietary limitation
such as caloric restriction and intermittent fasting are
the most-well known approaches in this category [40,
41]. Both are dietary regimens that involve reducing
calorie intake without causing malnutrition. Though
caloric restriction is a long-standing “gold standard”
in the aging field, and is associated with up to 50%
increases in lifespan (1), it has two major issues: 1) It
has poor feasibility. It is questionable whether many
humans could cut the large number of calories, e.g.,
33% reduction, needed long-term to demonstrate the
generalizable efficacy of this approach [42]; 2) more
importantly, though many studies including those dating back almost a century ago have showed significant
benefits of CR [43–45], many other studies haven’t
panned out [46–48]. How can CR work so well in
some contexts and not at all in others? Again, like
rapamycin, one has to wonder whether rather than
devote more resources to CR, there might be other
better approaches.
Therefore, instead of restricting something,
arguably a more defensible idea would be to restore
functionality. This makes sense considering aging
explicitly means decreasing function. How would one
simultaneously restore declining molecular functioning of various tissues, such as the bone [49], immune
system [50], and heart [51]? Parabiosis involving the
sharing of blood streams between young and old mice
provides a proof-of-concept for how we might add
back combinations of factors to restore functionality
throughout the body [52]. Though having a renewable, multiplexed source of “young” signaling that
doesn’t require another human’s involvement, such as
using extracellular vesicles [53], would seem a more
feasible approach.
While the benefits of restoring “young” signaling remain to be proven, preventing “old” signaling
using senolytics has already shown early promise in
humans [54, 55]. Senolytics are a newly described
class of drugs that selectively eliminate senescent
cells. Senescent cells are non-dividing cells that accumulate as people age that secrete various factors

242

S. Kumar and T.R. Peterson / Moonshots for aging

including cytokines that lead to damage of surrounding cells and tissue. In a first clinical trial involving
senolytics, dasatinib and quercetin were combined
and shown to alleviate physical dysfunction in
idiopathic pulmonary fibrosis [54]. Interestingly,
senolytics might be considered a combination therapy even when they are used as single agents because
senescent cells aren’t marked by a single molecular factor. Rather they defined by several not fully
specific molecular markers such as p16 and IL-6.
This means that combinations of markers need to be
assessed to judge the efficacy of senolytics.

3. Is measuring lifespan the right
experimental model?
As is the case in many areas of molecular biology,
some models get a lot of attention and others get less.
Measuring organismal lifespan – the time from birth
to death – is a core assay in the aging field. Why
then are we not studying trees or other examples of
extreme longevity more [56]? Trees are the longestlived species on earth living up to 5,000 years. They
have stem cells that actively divide and differentiate
throughout their existence [57]. They have many of
the same hub/core genes that humans have [58]. They
are enriched for pathways elevated in young mammalian tissues relative to their older counterparts [59,
60]. Therefore, shouldn’t there be principles there we
could learn more from? The mainstreaming of the
long-lived naked mole rat and various aquatic species
over the last few decades has brought many new ideas
to the aging field [61, 62]. Though some are starting
to the study longevity determinants in trees [63], it is
safe to say they are underexplored.
Measuring lifespan makes sense because we are
measuring the thing we want to improve. However,
can we identify factors that might extend life without measuring lifespan? In worms, being alive means
the worm moves, even if only slightly. Similarly, in
humans, a key symbolic if not medical part of being
considered alive means being able to respond to external cues. Both worms and people being considered
alive says nothing about quality of life though. In
worms, yes, one can disrupt mitochondria function
and that can extend lifespan in model organisms significantly, but would inhibiting such a key organelle
long-term in humans resemble anything like a normal
life?
In the spirit of pioneers, explorers, and astronauts
who couldn’t know where they were headed, instead

of measuring lifespan, perhaps one could aim for simpler goals. For example, we could figure out how to
maintain a young state on an incremental timescale.
The younger vs. older states could be defined, for
example, by determining the mRNA levels of various genes at the beginning and end of this timescale.
The key would be being able to detect slight differences in the levels of the factors of interest (i.e.,
biomarkers) between the two time points (Fig. 2).
Then once an intervention is identified that preserves
the young phenotype on this timescale, one would
seek to extrapolate it to longer timescales. This is, in
essence, a healthspan experiment rather than a lifespan experiment. Thus, if aren’t measuring lifespan,
what is an aging-relevant phenotype should we look
at? Replicative lifespan, which is the number of divisions a cell will undergo before it dies, decreases with
chronological age of the organism [64]. Measuring
cell replication is a simple model to evaluate small
differences in the young vs. slightly older state. Cell
number is an experimentally tractable phenotype, and
inexpensive to measure too. Though cell replication
rates are only one aspect of age and as many in the
aging field know manipulating replicative lifespan
might be considered a solved issue as telomerase
can confer immortal growth [65]. However, telomerase is re-activated in 90% of cancers and influences
DNA damage responses [66] but doesn’t influence
all core/hub genes, which suggests there are other
ways to toggle replicative lifespan. Nevertheless, to
identify robust, aging-relevant phenotypes, we seem
due for a comprehensive assessment of the molecular
differences between cells/tissues as they age.

4. Beyond molecular biology
Often discoveries in one field are made using
findings from orthogonal fields. The contemporary
internet stemming from efforts by the military to
build a communication network is a classic example
[67]. What principles from other disciplines could
be employed to help biologist tackle aging? Around
the time of World War II, physicists flooded into biology to help solve problems such as the structure of
DNA. Perhaps we could use their help again with
aging.
Thinking as an engineer, consider our bodies as
a car engine. While most of the aging biologist’s
focus has been on combustion and its linear pathway of energy generation, less attention has been on
the flywheel [68], which maximizes the energy from
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Fig. 2. 10X healthspan/lifespan strategy #2. Minimize agingrelated changes on a small timescale. Rather than waiting
a lifespan to observe the effects of a putative aging-delaying/
healthspan-increasing factor, one can measure an aging-relevant
phenotype, ρ, on small time scale (e.g., hours) and identify changes
that make the rate of change of the phenotype, i.e., derivative
(ρ/t), go from negative to 0. This requires highly quantitative,
rigorous experimentation.

combustion via its rotational momentum (Fig. 3). Flywheels also ensure a smooth ride such that when the
sparkplug sparks, we don’t feel a jolt due to the discontinuous action of the piston. This engine analogy
seems apt to aging because many in the aging field
have focused on the cellular sparkplugs, such as the
mitochondria, with less effort on what could be our
flywheel. Moreover, molecular biology is only one
way to make a flywheel. Perhaps we can generalize
the inputs to our body’s engine to include more factors than just biomolecules. Car flywheel moment of
inertias have been optimized to maximize fuel efficiency. What besides molecules might diminish our
moment of inertia as we get older?
Besides the molecular biology central dogma of
DNA, RNA, and protein, physical chemistry is underexplored for its role in aging. Could we make
any environmental changes (not detrimental to our
planet) that could keep our flywheels spinning? Is
our body temperature and the atmosphere we experience optimized for our healthspans and lifespans?
The effects of varying atmospheric gases has been
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Fig. 3. 10X healthspan/lifespan strategy #3. Identify ﬂywheels
that preserve our body’s energy. Engines work by gas injected
into its cylinders on regular intervals being ignited by a sparkplug spark. The gas is volatilized and expands, driving the piston,
which then turns the crankshaft. The crankshaft is attached to a flywheel and the wheels. The flywheel has a large moment of inertia
which maintains its rotation in between the time interval where the
sparkplug fires. Therefore, the flywheel both maximizes the energy
derived from the gas and smoothens the ride. It is currently unclear
whether any biomolecules or non-molecular factors function as a
flywheel to modulate human aging.

tested in the context of endurance athletes [69] and
with divers [70, 71], but to our knowledge not in
the context of aging. We know molecular oxygen is
important but what about other components of our
atmosphere? It is surprising how few studies have
measured the effects of the most abundant atmospheric gas, nitrogen, on human physiology [72].
Several species such as Geogemma barossii live at
extreme temperatures (250 degrees) [73]. There are
some correlations between external and internal temperatures and longevity in humans, but this should be
tested more systematically.
What about the potential, electrical, and mechanical energy of aging? We know lack of gravity leads to
decline in our muscles and bone that resembles aging
and mechanical forces such as exercise help delay
aging [74, 75]. However, exercising our muscles and
bones seems an inadequate way to fix all our aging
tissues. Is there a way to deliver mechanical forces to
other organs beyond our muscle and bones? Can we
exercise the liver? We have to be careful with the type
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of mechanical forces we apply though because in tissues such as the liver, mechanical forces that involve
blood flow congestion induce fibrosis that impairs its
function [76].
There are also many man-made factors that
profoundly affect aging. Social isolation strongly
negatively affects our health [77]. Socioeconomic
factors are too broad a discussion for this forum, but it
shouldn’t be a stretch to say focusing on them might
possibly produce larger global healthspan-extending
effects than many medical therapies.

5. Looking ahead
In summary, we laid out the first steps for
three potential strategies that we believe, if optimized, might have the potential to increase human
healthspan and/or lifespan beyond what’s currently
possible: 1) identify factors that strongly synergize
with each other, ideally without regard to number of
factors that need to be combined; 2) identify factors
that prevent age-associated changes over tractable
time increments and that retain their prophylactic
effects as the time interval is lengthened; 3) identify
factors that play a flywheel function for our bodies
to make them more energy efficient and balance fluctuations in our physiology. This review is a thought
exercise on what could we do if we could study anything we think might help with aging. At the same
time, constraints can also drive progress. In that light,
what would we do to combat aging if our knowledge
of molecular biology didn’t exist?
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